Anidulafungin is a semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis. It is an azamacrocycle, a heterodetic cyclic peptide, a semisynthetic derivative, an echinocandin and an antibiotic antifungal drug.
*The following content is generated by AI and is for reference only.
Anidulafungin is a potent semisynthetic echinocandin antifungal agent belonging to the class of glucan synthesis inhibitors. Chemically, its molecular formula is C56H83N9O17S2, and it carries the CAS registry number 169504-13-2. Structurally, this macrocyclic lipopeptide features a unique cyclic hexapeptide backbone linked to a fatty acid tail, which facilitates its interaction with fungal cell membranes. Unlike polyenes or azoles, Anidulafungin exerts its therapeutic effect by specifically inhibiting the enzyme beta-(1,3)-D-glucan synthase. This enzyme is essential for the biosynthesis of beta-glucan, a critical structural component of the fungal cell wall. By blocking this pathway, the drug induces osmotic instability, leading to cell lysis and death of susceptible fungi.
Clinically, Anidulafungin is primarily indicated for the treatment of invasive candidiasis and esophageal candidiasis in adults. It demonstrates broad activity against various Candida species, including multidrug-resistant strains such as Candida glabrata and Candida krusei. Notably, it possesses no intrinsic activity against Aspergillus species or Cryptococcus neoformans. One of its distinct advantages is its favorable pharmacokinetic profile; it undergoes spontaneous chemical degradation in plasma rather than hepatic metabolism, making it safe for patients with liver dysfunction. Furthermore, it exhibits minimal drug-drug interactions, simplifying its use in complex clinical settings involving multiple medications. The drug is administered exclusively via intravenous infusion due to poor oral bioavailability. Its safety profile is generally well-tolerated, with common adverse effects including gastrointestinal disturbances, headache, and transient elevations in liver enzymes. Given its mechanism of action and efficacy, Anidulafungin serves as a crucial first-line therapy for serious systemic fungal infections, particularly in immunocompromised populations where rapid fungicidal activity is required to prevent mortality.